Association between use of HMG coa reductase inhibitors and mortality in HIV-Infected patients

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Moore, Richard D ^a   Bartlett, John G ^a   Gallant, Joel E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHOLESTEROL; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; CAUSE OF DEATH; CHRONIC INFLAMMATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; RACE DIFFERENCE; VIRUS HEPATITIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; CAUSE OF DEATH; FEMALE; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 79960202601     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021843     Document Type: Article

References (35)

1. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, et al. (2010) Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 201: 1788-95.
2. Deeks SG, (2011) HIV infection, inflammation, immunosenescence, and aging. Ann Rev Med 62: 141-55.
3. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, et al. (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5: e203.
4. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1 365-71.
5. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, et al. (2009) Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 199: 1177-85.
6. Molina-Pinelo S, Vallejo A, Diaz L, Soriano-Sarabia N, Ferrando-Martinez S, et al. (2009) Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation. J Antimicrob Chemother 64: 579-88.
7. Hunt PW, (2007) Role of immune activation in HIV pathogenesis Curr HIV/AIDS Rep 4: 42-7.
8. Appay V, Sauce D, (2008) Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 214: 231-41.
9. Deeks SG, (2009) Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med 17: 118-23.
10. Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, et al. (2009) Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 23: 841-49.
11. Monforte A, Abrams D, Pradier C, Weber R, Peiss P, et al. (2008) HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 22: 2143-53.
12. Longenecker CT, Scherzer R, Bacchetti P, Weber R, Reiss P, et al. (2009) HIV viremia and changes in kidney function. AIDS 23: 1089-96.
13. Moore RD, Gebo KA, Lucas GM, Keruly JC, (2008) Rates of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status. Clin Infect Dis 47: 1102-4.
14. Jain MK, Ridker PM, (2005) Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 4: 977-87.
15. Ganesan A, Crum-Cianflone N, Higgins J, Qin J, Rehm C, et al. (2011) High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: Results of a double-blind randomized placebo controlled clinical trial. J Infect Dis 203: 756-64.
16. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, et al. (2009) Reduction in C-reactive protein, and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373: 1175-82.
17. Kwak B, Mulhaupt F, Myit S, Mach F, (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6: 1399-402.
18. Mira E, Manes S, (2009) Immunomodulatory and anti-inflammatory activities of statins. Endocr Metab Immune Disord Drug Targets 9: 237-47.
19. Dulak J, Jozkowicz A, (2005) Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy, Curr Cancer Drug Targets 5: 579-94.
20. Jadhav SB, Jain GK, (2006) Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol 58: 3-18.
21. Yokota N, O'Donnell M, Daniels F, Burne-Taney M, Keane W, et al. (2003) Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. Am J Nephrol 23: 13-7.
22. Yasuda H, Yuen PS, Hu X, Zhou H, Star RA, (2010) Simvastatin improves sepsis-induced mrtality and acute kidney injury via renal vascular effects, Kidney Int 2006; 69: 1535-42. Chalmers JD, Short PM, Mandal P, Akram AR, Hill AT Statins in community acquired pneumonia: Evidence from experimental and clinical studies. Respir Med 104: 1081-91.
23. Kopterides P, Falagas ME, (2009) Statins for sepsis: a critical and updated review. Clin Microbiol Infect 15: 325-34.
24. Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J, (2010) The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care 25: 656.e7-22.
25. Fedson DS, (2008) Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis 6: 571-6.
26. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, et al. (2009) Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 69: 1658-67.
27. Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, et al. (2008) Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med 168: 2081-7.
28. Moore RD, (1998) Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV Clinical Practice Cohort. J Acquir Immune Defic Syndr 17 (Suppl.1): S38-S41.
29. Maryland Department of Health and Mental Hygiene (2010) Maryland HIV/AIDS Epidemiological Profile. Fourth Quarter 2009. Available: http://dhmh.state.md.us?AIDS/Data&Statistics?marylandHIVEpiPRofile12 -2009.pdf. Accessed 2011 March 14.
30. Moncunill G, Negredo E, Bosch L, Vilarrasa J, Witvrouw M, et al. (2005) Evaluation of the anti-HIV activity of statins. AIDS 19: 1697-700.
31. Amet T, Nonaka M, Dewan MZ, Saitoh Y, Qi X, et al. (2008) Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication. Microbes Infect 10: 471-80.
32. Negredo E, Clotet B, Puig J, Pérez-Alvarez N, Ruiz L, et al. (2006) The effect of atorvastatin treatment on HIV-1-infectedpatients interrupting antiretroviral therapy. AIDS 20: 619-21.
33. Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, et al. (2008) Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther 13: 959-67.
34. Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, et al. (1999) Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 13: 943-50.
35. Price EA, Schrier SL, (2010) Unexplained aspects of anemia of inflammation. Adv Hematol 508739.